← Leaderboards
Karen Lashea Posey
University Of Texas Hlth Sci Ctr Houston
$1,283,890
Attributed
$2,567,780
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $527K · FY2016–20$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,567,780 · 1
By mechanism
R01$2,567,780 · 1
Top collaborators
- Jacqueline T Hecht5 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Lenard M Lichtenberger$8,121,394
- Jocelyne H Bachevalier$13,246,208
- Donald M Dougherty$27,746,313
- Jacqueline T Hecht$11,161,560
- James J Knierim$18,682,597
Others in their field
Top investigators on “Emerging Adult”
- Barbara Driver · Westat, Inc.$117,383,247
- Peter C Adamson · National Childhood Cancer Foundation$115,672,048
- Judith S. Currier · University Of California Los Angeles$112,806,260
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$84,065,049
- Gregory H Reaman · National Childhood Cancer Foundation$63,142,489
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,218,842
Research focus
Emerging AdultEpiphysial CartilageEarly OnsetAntisense OligonucleotidesEarly ChildhoodAntioxidantsAntioxidant TherapyArticular CartilageAspirinAutophagocytosisAntisense Oligonucleotide TherapyBiological Adaptation To StressBirthApoptosisBone GrowthArthralgiaChildhoodChondrocytesClinical TrialsDegenerative PolyarthritisDesignDosageBaseEvent
Grant awards (5)
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic Mice$510,205
R01 · FY2020 · AR
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic Mice$510,205
R01 · FY2019 · AR
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic Mice$510,205
R01 · FY2018 · AR
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic Mice$510,205
R01 · FY2017 · AR
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic Mice$526,960
R01 · FY2016 · AR